Aurinia Data At EULAR 2026 And Insider Buys Shape LUPKYNIS Outlook

Simply Wall St.05:32

Aurinia Pharmaceuticals (NasdaqGM:AUPH) reported new AURORA 1 Phase 3 data at EULAR 2026 showing LUPKYNIS reduced the risk of renal events or death in lupus nephritis. The findings were presented at a...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2641120285?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-06-07 05:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2641120285","market":"nz","top_or_hot":-1,"title":"Aurinia Data At EULAR 2026 And Insider Buys Shape LUPKYNIS Outlook","media":"Simply Wall St.","content":"<div>\n<p>Aurinia Pharmaceuticals (NasdaqGM:AUPH) reported new AURORA 1 Phase 3 data at EULAR 2026 showing LUPKYNIS reduced the risk of renal events or death in lupus nephritis. The findings were presented at a...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-auph/aurinia-pharmaceuticals/news/aurinia-data-at-eular-2026-and-insider-buys-shape-lupkynis-o\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aurinia Data At EULAR 2026 And Insider Buys Shape LUPKYNIS Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAurinia Data At EULAR 2026 And Insider Buys Shape LUPKYNIS Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-07 05:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-auph/aurinia-pharmaceuticals/news/aurinia-data-at-eular-2026-and-insider-buys-shape-lupkynis-o><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Aurinia Pharmaceuticals (NasdaqGM:AUPH) reported new AURORA 1 Phase 3 data at EULAR 2026 showing LUPKYNIS reduced the risk of renal events or death in lupus nephritis. The findings were presented at a...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-auph/aurinia-pharmaceuticals/news/aurinia-data-at-eular-2026-and-insider-buys-shape-lupkynis-o\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-auph/aurinia-pharmaceuticals/news/aurinia-data-at-eular-2026-and-insider-buys-shape-lupkynis-o","article_id":"2641120285","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-auph/aurinia-pharmaceuticals/news/aurinia-data-at-eular-2026-and-insider-buys-shape-lupkynis-o","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2641120285","pubTimestamp":1780781551,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Aurinia Pharmaceuticals (NasdaqGM:AUPH) reported new AURORA 1 Phase 3 data at EULAR 2026 showing LUPKYNIS reduced the risk of renal events or death in lupus nephritis.\nThe findings were presented at a major international rheumatology congress, putting fresh clinical evidence for LUPKYNIS in front of global specialists.\nTang Capital Management increased its stake in Aurinia, and senior company executives acquired additional shares.\n\nAurinia focuses on therapies for autoimmune kidney disease,...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","AUPH":"Aurinia Pharmaceuticals Inc"},"translate_title":"EULAR 2026的Aurinia数据和内部购买塑造了LUPKYNIS的前景","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AUPH":0.9},"content_text":"Aurinia Pharmaceuticals (NasdaqGM:AUPH) reported new AURORA 1 Phase 3 data at EULAR 2026 showing LUPKYNIS reduced the risk of renal events or death in lupus nephritis. The findings were presented at a major international rheumatology congress, putting fresh clinical evidence for LUPKYNIS in front of global specialists. Tang Capital Management increased its stake in Aurinia, and senior company executives acquired additional shares.  Aurinia focuses on therapies for autoimmune kidney disease, with LUPKYNIS targeting lupus nephritis, a serious condition with limited treatment options. Fresh Phase 3 data presented at a high profile meeting keeps clinical outcomes in the spotlight and gives investors more detail on how the therapy performs in advanced studies. For readers tracking NasdaqGM:AUPH, the mix of new trial data and higher ownership by a large institutional investor and company insiders is an important combination to watch. It ties real world corporate actions to clinical progress at a time when many investors are focused on product traction and the durability of the underlying drug franchise. Stay updated on the most important news stories for Aurinia Pharmaceuticals by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Aurinia Pharmaceuticals. NasdaqGM:AUPH 1-Year Stock Price Chart See which insiders are buying and buying and selling Aurinia Pharmaceuticals following this latest news. The new AURORA 1 analysis gives investors more detail on how LUPKYNIS performs on hard outcomes that matter for payers and physicians. A 53% reduction in the risk of renal events or death, and favorable hazard ratios across death, treatment failure and worsening proteinuria, help support the clinical rationale for use in lupus nephritis. For a company with heavy reliance on a single kidney-drug franchise, this kind of data can be important when nephrologists compare options from larger autoimmune players such as GSK, AstraZeneca or Roche. AdvertisementHow This Fits Into The Aurinia Pharmaceuticals Narrative  The EULAR 2026 data is consistent with the narrative that LUPKYNIS can support long-term revenue by reinforcing its role in treatment guidelines for autoimmune kidney disease. Continued focus on one product also highlights the narrative risk that Aurinia is concentrated in a single therapy. Any change in clinical perception or reimbursement could still weigh heavily on the story. The increased ownership by Tang Capital Management and additional executive share purchases add an investor-sentiment angle that is not fully captured in the existing narrative around operations and pipeline.  Knowing what a company is worth starts with understanding its story.\n Check out one of the top narratives in the Simply Wall St Community for Aurinia Pharmaceuticals to help decide what it's worth to you. The Risks and Rewards Investors Should Consider  ⚠️ Analysts have flagged that earnings are forecast to decline on average over the next three years, which can limit how much value investors place on positive data points from a single study. ⚠️ Dependence on LUPKYNIS and high non cash earnings leave the company exposed if future trials, pricing or competitive moves from larger biotech peers change sentiment. 🎁 The strong AURORA 1 outcomes and guideline support for LUPKYNIS back up one of the key rewards flagged by analysts, that revenue has been growing and is forecast to keep growing. 🎁 Tang Capital Management lifting its stake to about 10% and insider buying by the CEO and other executives signal that a large shareholder group and management are aligning more directly with outside investors.  What To Watch Going Forward From here, investors can monitor how quickly the new EULAR 2026 data is reflected in prescribing trends and reimbursement discussions, and whether competitors launch new lupus nephritis drugs that challenge LUPKYNIS. On the capital side, investors may also track any further ownership changes by Tang Capital Management, shifts in insider buying patterns, and updates on Aurinia’s second asset, aritinercept, which is intended to diversify the autoimmune portfolio over time. To stay informed on how the latest news affects the investment narrative for Aurinia Pharmaceuticals, visit the\n community page for Aurinia Pharmaceuticals to keep up with the top community narratives.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2641120285","isCrawlerRequest":true}